Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma

Przybyla,Beata   D.; Shafirstein,Gal; Vishal,Sagar   J.; Dennis,Richard   A.; Griffin,Robert   J.

doi:10.3892/ijo.2013.2185

Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma

Authors:
- Beata D. Przybyla
- Gal Shafirstein
- Sagar J. Vishal
- Richard A. Dennis
- Robert J. Griffin
View Affiliations

Affiliations: Department of Radiation Oncology, University of Arkansas for Medical Science, Little Rock, AR, USA, Department of Cell Stress Biology and Otolaryngology, Roswell Park Cancer Institute, Buffalo, NY, USA, College of Medicine, University of Arkansas for Medical Science, Little Rock, AR, USA, Geriatric Research Education and Clinical Center, Central Arkansas Veteran Healthcare System, Little Rock, AR, USA
Published online on: November 21, 2013 https://doi.org/10.3892/ijo.2013.2185
Pages: 600-608

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thermal ablation of solid tumors using conductive interstitial thermal therapy (CITT) produces coagulative necrosis in the center of ablation. Local changes in homeostasis for surviving tumor and systemic changes in circulation and distant organs must be understood and monitored in order to prevent tumor re-growth and metastasis. The purpose of this study was to use a mouse carcinoma model to evaluate molecular changes in the bone marrow and surviving tumor after CITT treatment by quantification of transcripts associated with cancer progression and hyperthermia, serum cytokines, stress proteins and the marrow/tumor cross-talk regulator stromal-derived factor 1. Analysis of 27 genes and 22 proteins with quantitative PCR, ELISA, immunoblotting and multiplex antibody assays revealed that the gene and protein expression in tissue and serum was significantly different between ablated and control mice. The transcripts of four genes (Cxcl12, Sele, Fgf2, Lifr) were significantly higher in the bone marrow of treated mice. Tumors surviving ablation showed significantly lower levels of the Lifr and Sele transcripts. Similarly, the majority of transcripts measured in tumors decreased with treatment. Surviving tumors also contained lower levels of SDF-1α and HIF-1α proteins whereas HSP27 and HSP70 were higher. Of 16 serum chemokines, IFNγ and GM-CSF levels were lower with treatment. These results indicate that CITT ablation causes molecular changes which may slow cancer cell proliferation. However, inhibition of HSP27 may be necessary to control aggressiveness of surviving cancer stem cells. The changes in bone marrow are suggestive of possible increased recruitment of circulatory cancer cells. Therefore, the possibility of heightened bone metastasis after thermal ablation needs to be further investigated and inhibition strategies developed, if warranted.

View Figures

View References

1.	Shah DR, Green S, Elliot A, McGahan JP and Khatri VP: Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol. 5:71–80. 2013. View Article : Google Scholar : PubMed/NCBI
2.	Oto A, Sethi I, Karczmar G, et al: MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 267:932–940. 2013. View Article : Google Scholar : PubMed/NCBI
3.	Merckel LG, Bartels LW, Kohler MO, et al: MR-guided high-intensity focused ultrasound ablation of breast cancer with a dedicated breast platform. Cardiovasc Intervent Radiol. 36:292–301. 2013. View Article : Google Scholar : PubMed/NCBI
4.	Shafirstein G, Hennings L, Kaufmann Y, et al: Conductive interstitial thermal therapy (CITT) device evaluation in VX2 rabbit model. Technol Cancer Res Treat. 6:235–246. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Shafirstein G, Novák P, Moros EG, et al: Conductive interstitial thermal therapy device for surgical margin ablation: in vivo verification of a theoretical model. Int J Hyperthermia. 23:477–492. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Shafirstein G, Kaufmann Y, Hennings L, et al: Conductive interstitial thermal therapy (CITT) inhibits recurrence and metastasis in rabbit VX2 carcinoma model. Int J Hyperthermia. 25:446–454. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Przybyla BD, Shafirstein G, Koonce NA, Webber JS and Griffin RJ: Conductive thermal ablation of 4T1 murine breast carcinoma reduces severe hypoxia in surviving tumour. Int J Hyperthermia. 28:156–162. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Dromi SA, Walsh MP, Herby S, et al: Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 251:58–66. 2009. View Article : Google Scholar : PubMed/NCBI
9.	van der Bilt JD, Soeters ME, Duyverman AM, et al: Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol. 170:1379–1388. 2007.PubMed/NCBI
10.	Peters BA, Diaz LA, Polyak K, et al: Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 11:261–262. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Bunt SK, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 176:284–290. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Di Rosa F: T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow. Immunol Cell Biol. 87:20–29. 2009.PubMed/NCBI
13.	Evans SS, Fisher DT, Skitzki JJ and Chen Q: Targeted regulation of a lymphocyte-endothelial-interleukin-6 axis by thermal stress. Int J Hyperthermia. 24:67–78. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Peer AJ, Grimm MJ, Zynda ER and Repasky EA: Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res. 46:137–154. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Baronzio G, Gramaglia A and Fiorentini G: Hyperthermia and immunity. A brief overview. In Vivo. 20:689–695. 2006.PubMed/NCBI
16.	Chantrain CF, Feron O, Marbaix E and DeClerck YA: Bone mrrow microenvironment and tumor progression. Cancer Microenviron. 1:23–35. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Heppner GH, Miller FR and Shekhar PM: Nontransgenic models of breast cancer. Breast Cancer Res. 2:331–334. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Lippold HJ: Quantitative succinic dehydrogenases histochemistry. A comparison of different tetrazolium salts. Histochemistry. 76:381–405. 1982. View Article : Google Scholar : PubMed/NCBI
19.	Schmittgen TD, Lee EJ and Jiang J: High-throughput real-time PCR. Methods Mol Biol. 429:89–98. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Wiggermann P, Zeman F, Niessen C, et al: Percutaneous irreversible electroporation (IRE) of hepatic malignant tumours: contrast-enhanced ultrasound (CEUS) findings. Clin Hemorheol Microcirc. 52:417–427. 2012.
21.	Uchida T, Nakano M, Hongo S, et al: High-intensity focused ultrasound therapy for prostate cancer. Int J Urol. 19:187–201. 2011. View Article : Google Scholar
22.	Zhao Z and Wu F: Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. Eur J Surg Oncol. 36:1149–1155. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Yoon J, Cho J, Kim N, et al: High-frequency microwave ablation method for enhanced cancer treatment with minimized collateral damage. Int J Cancer. 129:1970–1978. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Hung WK, Mak KL, Ying M and Chan M: Radiofrequency ablation of breast cancer: a comparative study of two needle designs. Breast Cancer. 18:124–128. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Nijkamp MW, van der Bilt JD, de Bruijn MT, et al: Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg. 249:814–823. 2009. View Article : Google Scholar
26.	St Hill CA: Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci. 16:3233–3251. 2011.PubMed/NCBI
27.	Hofer EL, Labovsky V, La Russa V, et al: Mesenchymal stromal cells, colony-forming unit fibroblasts, from bone marrow of untreated advanced breast and lung cancer patients suppress fibroblast colony formation from healthy marrow. Stem Cells Dev. 19:359–370. 2010. View Article : Google Scholar
28.	Oskowitz AZ, Lu J, Penfornis P, et al: Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc Natl Acad Sci USA. 105:18372–18377. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Whitney MJ, Lee A, Ylostalo J, Zeitouni S, Tucker A and Gregory CA: Leukemia inhibitory factor secretion is a predictor and indicator of early progenitor status in adult bone marrow stromal cells. Tissue Eng Part A. 15:33–44. 2009. View Article : Google Scholar : PubMed/NCBI
30.	McAllister SS and Weinberg RA: Tumor-host interactions: a far-reaching relationship. J Clin Oncol. 28:4022–4028. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Castano Z, Tracy K and McAllister SS: The tumor macro-environment and systemic regulation of breast cancer progression. Int J Dev Biol. 55:889–897. 2011. View Article : Google Scholar : PubMed/NCBI
32.	Hirbe AC, Morgan EA and Weilbaecher KN: The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des. 16:1284–1290. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Meads MB, Hazlehurst LA and Dalton WS: The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 14:2519–2526. 2008. View Article : Google Scholar : PubMed/NCBI
34.	Cronin PA, Wang JH and Redmond HP: Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer. 10:2252010. View Article : Google Scholar : PubMed/NCBI
35.	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Kucia M, Jankowski K, Reca R, et al: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Petit I, Jin D and Rafii S: The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28:299–307. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Du R, Lu KV, Petritsch C, et al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 13:206–220. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Sceneay J, Chow MT, Chen A, et al: Primary tumor hypoxia recruits CD11b⁺/Ly6Cmed/Ly6G⁺ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72:3906–3911. 2012.PubMed/NCBI
40.	Murphy ME: The HSP70 family and cancer. Carcinogenesis. 34:1181–1188. 2013. View Article : Google Scholar : PubMed/NCBI
41.	Teng LS, Jin KT, Han N and Cao J: Radiofrequency ablation, heat shock protein 70 and potential anti-tumor immunity in hepatic and pancreatic cancers: a minireview. Hepatobiliary Pancreat Dis Int. 9:361–365. 2010.PubMed/NCBI
42.	Ciocca DR and Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 10:86–103. 2005. View Article : Google Scholar : PubMed/NCBI
43.	Gibert B, Hadchity E, Czekalla A, et al: Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene. 30:3672–3681. 2011. View Article : Google Scholar : PubMed/NCBI
44.	Wei L, Liu TT, Wang HH, et al: Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappaB. Breast Cancer Res. 13:R1012011. View Article : Google Scholar : PubMed/NCBI
45.	Hsu HS, Lin JH, Huang WC, et al: Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer. 117:1516–1528. 2011. View Article : Google Scholar : PubMed/NCBI
46.	Lin EY, Gouon-Evans V, Nguyen AV and Pollard JW: The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia. 7:147–162. 2002. View Article : Google Scholar : PubMed/NCBI
47.	Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P and Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 87:21–27. 2002. View Article : Google Scholar : PubMed/NCBI
48.	Haen SP, Pereira PL, Salih HR, Rammensee HG and Gouttefangeas C: More than just tumor destruction: immuno-modulation by thermal ablation of cancer. Clin Dev Immunol. 2011:1602502011.PubMed/NCBI
49.	Li J, Bouton-Verville H, Holmes LM, et al: Inhibition or promotion of tumor growth by granulocyte-macrophage colony stimulating factor derived from engineered tumor cells is dose-dependent. Anticancer Res. 24:2717–2721. 2004.PubMed/NCBI
50.	Eubank TD, Roberts RD, Khan M, et al: Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res. 69:2133–2140. 2009. View Article : Google Scholar